Latest Research
All publications from the Cancer3.AI database, newest first.
A robust vision language model for molecular status prediction and radiology report generation in adult-type diffuse gliomas.
Park YW, et al
Researchers developed Glio-LLaMA-Vision, an artificial intelligence model combining image analysis and language generation, designed to assist clinicians in diagnosing adult-type diffuse gliomas — a group of aggressive brain tumors. The model was trained on multiparametric MRI scans and paired radiology reports from over 1,000 patients, then validated across four independent datasets totaling more than 800 additional patients. For predicting IDH mutation status — a key molecular marker that guides treatment and prognosis — the model achieved strong accuracy with AUC values between 0.85 and 0.95 across all tested datasets. When tasked with automatically generating radiology reports from MRI images, 91% of the AI-produced reports were judged clinically acceptable by neuroradiologists, and over one-third were considered equal to or better than reports written by human specialists. These results suggest that Glio-LLaMA-Vision could meaningfully support neuroradiologists in busy clinical settings by accelerating diagnosis and reducing the burden of report writing for brain tumor patients.
NPJ digital medicine
Source →Descemet membrane endothelial keratoplasty in patients after radiation therapy for uveal melanoma.
Maier AB, et al
A new study from Charité – Universitätsmedizin Berlin evaluated the safety and effectiveness of Descemet membrane endothelial keratoplasty (DMEK), a type of corneal transplant surgery, in nine patients who had previously undergone radiation therapy for uveal melanoma, a rare eye cancer. Researchers found that the surgery significantly improved best-corrected visual acuity three months after the procedure, with gains maintained at 12 and 24 months, demonstrating that DMEK is a viable option for restoring vision in this challenging patient group. However, the complication rate was notably high: more than half of patients required a repeat procedure called re-bubbling, one in four experienced graft failure within two years, over half developed elevated intraocular pressure, and nearly one in six developed post-operative glaucoma. Endothelial cell density — a key measure of transplant health — declined substantially in the months following surgery, and radiation-related damage to other eye structures limited the overall visual improvement achievable. The findings suggest that while DMEK can benefit patients whose uveal melanoma is under local control, clinicians must carefully weigh the elevated risk of complications specific to this population when planning treatment. This retrospective study highlights the need for larger prospective trials to better define outcomes and refine patient selection criteria for this procedure.
BMC ophthalmology
Source →MYCN Amplification in RB1-Inactivated Retinoblastoma: Association With High-Risk Features.
Papaioannou K, et al
Researchers at a German reference center examined 139 unilateral retinoblastoma samples from children who underwent eye removal between 2011 and 2018, focusing on the role of MYCN gene amplification in tumor aggressiveness. The study found that MYCN gain or amplification was present in 7.2% of cases, and notably, all affected tumors also carried inactivation of the RB1 gene, challenging previous suggestions that MYCN-amplified retinoblastoma is a distinct entity arising independently of RB1 loss. Tumors with MYCN amplification were significantly more likely to show secondary glaucoma, massive choroidal invasion, and scleral invasion compared to non-amplified tumors, indicating a more aggressive disease course. No cases of cancer spreading outside the eye or to distant sites were observed during a median follow-up of about four years. These findings are clinically important because identifying MYCN amplification at diagnosis may help oncologists and ophthalmologists better stratify patients by risk and tailor treatment decisions for children with this rare childhood eye cancer.
Pediatric blood & cancer
Source →Retinoblastoma Proficient Small Cell Carcinoma: A Novel Entity with Therapeutic Vulnerability?
Dowlati A, et al
Researchers reviewed the emerging understanding of a rare subset of small-cell lung cancer (SCLC) that retains a functional retinoblastoma (Rb) protein, a feature absent in the vast majority of SCLC cases. This Rb-proficient subtype appears to have distinct molecular characteristics, including possible links to YAP1 signaling and non-neuroendocrine gene expression patterns, setting it apart from classical SCLC. Preclinical evidence suggests that tumors retaining Rb protein may be uniquely sensitive to CDK4/6 inhibitors, a class of drugs already used in other cancers, and that these drugs may also modify the tumor immune environment to enhance the effectiveness of immunotherapy. The status of the RB1 gene may additionally influence how patients respond to other treatment approaches, broadening its clinical significance. These findings highlight the importance of molecularly classifying SCLC patients based on RB1 status to identify those who might benefit from targeted, precision therapies, offering new hope in a disease historically resistant to treatment advances.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Source →Methionine aminopeptidase 1D preserves myogenic cell integrity via maintaining mitochondrial activity.
Tsai C, et al
Researchers investigated the role of a mitochondrial enzyme called methionine aminopeptidase 1D (Metap1D) in muscle precursor cells, focusing on how it influences energy metabolism, cell growth, and muscle development. Using a gene-silencing technique (siRNA) in mouse muscle cells (C2C12 myoblasts), the team found that suppressing Metap1D led to increased mitochondrial content, higher mitochondrial membrane potential, and elevated ATP production, suggesting the enzyme normally restrains mitochondrial activity. Interestingly, short-term suppression of Metap1D initially boosted cell proliferation, but prolonged suppression reduced it, indicating a complex time-dependent role in cell cycle regulation. Critically, loss of Metap1D impaired muscle differentiation, resulting in abnormally shaped, spherical multinucleated muscle fibers and reduced expression of key muscle-building proteins such as myogenin and myosin heavy chain. These findings identify Metap1D as an important regulator of both mitochondrial function and muscle cell development, with potential implications for understanding muscle diseases and conditions involving impaired muscle regeneration.
Experimental cell research
Source →